SEC Comment Letter for Quince Therapeutics, Inc. (QNCX) (CIK 0001662774) (IRLA) — Apr 8, 2020
Quince Therapeutics, Inc. (QNCX) (CIK 0001662774)
Date: April 8, 2020 · CIK: 0001662774 · Accession: 0000000000-20-003043
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237594
Letter
April 8, 2020 Casey C. Lynch President and Chief Executive Officer Cortexyme, Inc. 269 East Grand Ave. South San Francisco, CA 94080 Re:Cortexyme, Inc. Registration Statement of Form S-1 Filed April 7, 2020 File No. 333-237594 Dear Ms. Lynch: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Niki Fang, Esq.
Show Raw Text
April 8, 2020
Casey C. Lynch
President and Chief Executive Officer
Cortexyme, Inc.
269 East Grand Ave.
South San Francisco, CA 94080
Re:Cortexyme, Inc.
Registration Statement of Form S-1
Filed April 7, 2020
File No. 333-237594
Dear Ms. Lynch:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Niki Fang, Esq.